An observational study in Joint Disease, sponsored by MicroPort Orthopedics Inc.. Active, not recruiting at 1 site in Canada. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.
Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2014, is one of 20 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 2nd registered.
386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.
Browse Joint Diseases studies →5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:
MicroPort Orthopedics Inc. · Sites in Italy
Ages 21+
MicroPort Orthopedics Inc. · Sites in United States, United Kingdom
Ages 21+
MicroPort Orthopedics Inc. · Sites in United States
Ages 21+
MicroPort Orthopedics Inc. · Sites in Poland
MicroPort Orthopedics Inc. · Sites in Germany
Ages 21+
By country, each count listing its studies:
Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2014.
This study's planned enrollment of 143 is above the median of 86 across 116 observational studies indexed under Joint Diseases.
Median enrollment 0 across the 1 interventional studies, 69 across the 20 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MicroPort Orthopedics Inc., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort Orthopedics Inc. is the lead sponsor of 26 studies on the registry; 6 are open to participants now.
3 of the studies in Joint Diseases by MicroPort Scientific Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02351414MicroPort Orthopedics Inc.Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts | 2027-06 |
| NCT02823834MicroPort Orthopedics Inc.PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components | 2027-06 |
| NCT02239783MicroPort Orthopedics Inc.Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) marketed in the European Union (EU) . These types of studies are required by regulatory authorities for all THA devices that do not have clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with MEDDEV 2.12/2 rev 2.
Total hip arthroplasty (THA) has been performed since the early 1920s and is generally considered to be one of the most successful orthopedic surgeries performed. The 8th Annual Report from the National Joint Registry of England and Wales reported 95.3% component survivorship at 7 years for over 300,000 THA implantations. MicroPort Orthopedics, Inc. (MPO) currently markets several THA components throughout the world, including the European Union (EU). As part of the process for gaining approval to market in the EU, MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of these THA components. The objectives of this study are to evaluate component survivorship and total functional outcome scores of implanted subjects at out to 10 years follow-up.
Patients who have been previously implanted with a primary PROFEMUR® TL Modular Femoral Stem
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
Device: total hip arthroplasty implant
Also known as: PROFEMUR® TL modular femoral stem
Component Survivorship
The primary objective of this study is to estimate component survivorship of all components out to 10 years follow-up.
Time frame: 10 years post-operative
Patient functional outcomes
The secondary objective is to characterize total functional scores, as assessed by HOOS scores and EQ-5D-3L scores.
Time frame: Screening (First Available), 2-5 years, 5-7 years, and 10 years
Started Nov 2014 (actual). Primary completion is estimated for Nov 2027, 156 months after the start.
Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 156 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.